BERLIN (Reuters) – Genetic testing specialist Qiagen received emergency use authorization for a new coronavirus test from the U.S. drugs regulator FDA, it said on Monday.
“This polymerase chain reaction (PCR) multiplex test will be an important tool now and in upcoming winter seasons for simultaneous qualitative detection and differentiation of influenzas A and B, respiratory syncytial virus (RSV) and SARS-CoV-2 infections within 80 minutes,” the company said in a statement.
Qiagen shares rose 2.8% in early Frankfurt trade.
(Reporting by Kirsti Knolle; Editing by Riham Alkousaa)
